Lindsey Roberts
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,922 and has fallen 94.1% since, to $113 in 2024.
Across 153 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$738
- Lilly USA, LLC$262
- Tandem Diabetes Care, Inc.$227
- Esperion Therapeutics, Inc.$175
- Dexcom, Inc.$174
- Sanofi-aventis U.S. LLC$173
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,175100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $738 |
| Lilly USA, LLC | 15 | $262 |
| Tandem Diabetes Care, Inc. | 4 | $227 |
| Esperion Therapeutics, Inc. | 4 | $175 |
| Dexcom, Inc. | 9 | $174 |
| Sanofi-aventis U.S. LLC | 4 | $173 |
| Insulet Corporation | 4 | $134 |
| AstraZeneca | 8 | $129 |
| Xeris Pharmaceuticals, Inc. | 6 | $126 |
| Corcept Therapeutics | 5 | $100 |
| IBSA Pharma Inc. | 4 | $75 |
| Radius Health, Inc. | 3 | $71 |
| Boehringer Ingelheim | 3 | $68 |
| Mannkind Corporation | 3 | $66 |
| Merck | 4 | $60 |
| AbbVie | 4 | $59 |
| Amgen | 3 | $48 |
| Vivus LLC | 3 | $44 |
| Nestle Healthcare Nutrition Inc. | 2 | $43 |
| Ascendis Pharma Endocrinology Inc | 1 | $42 |
| Novartis | 3 | $41 |
| Bayer | 2 | $40 |
| Antares Pharma, Inc. | 2 | $37 |
| Lifescan, Inc. | 1 | $35 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| Teleflex LLC | 2 | $28 |
| Medtronic | 1 | $26 |
| Averitas Pharma Inc. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| GRT US Holding, Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$247
- NEXLIZET$125
- NEXLETOL$125
- t:slim X2 Insulin Pump with Control-IQ$113
How this compares
$3,175 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.
Other family in Cary
- Amanda KellyCary$94K
- Daria LewisCary$66K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.